📄 What This Document Is

This is a Form 6-K, a special report that foreign companies (like this Dutch one) must file with the U.S. Securities and Exchange Commission (SEC) when they release important news to investors in their home country.

Think of it as an official "news alert" for American investors. This specific filing is just a formal announcement that the company has published its 2025 Annual Report and its detailed Form 20-F (the comprehensive annual report for non-U.S. companies).

👉 Why it matters: It’s the official signal that all the audited financial results and business details for the full year 2025 are now publicly available.

🏢 What Pharming Group Does

👉 In simple terms, Pharming is a global biotech company that develops and sells medicines for rare, serious diseases.

They focus on creating both small molecule drugs (traditional pills) and biologics (more complex medicines made from living cells). They are headquartered in the Netherlands but have a major presence in the United States. Their stock trades on exchanges in both Amsterdam (PHARM) and Nasdaq (PHAR).

🚀 The Key Action: Annual Reports Filed

The core news here is administrative but crucial: Pharming has officially filed two versions of its 2025 yearly report.

• The 2025 Annual Report: This is the main shareholder report, available on their own website at annualreport.pharming.com.
• The Form 20-F: This is the SEC-mandated version of the annual report, containing the same detailed information but formatted for U.S. regulators. It will be available on the "Investors/SEC filings" section of Pharming.com and directly on the SEC's website.

📅 Why This Date & What's Next

The filing is dated April 2, 2026. This timing is standard, as companies typically release their audited full-year results in the spring.

👉 What's next for investors: Anyone interested in Pharming’s financial health, pipeline progress, and strategy for 2025 should now review these documents. The annual report is where you’ll find the complete story behind the year’s results. No specific future events are announced in this filing.

🔍 The Details: Where to Find Everything

The company made a point of telling you exactly where to look:

• For the pretty report: annualreport.pharming.com
• For the SEC filing: Pharming.com (under Investors/SEC filings) or the SEC's own EDGAR database.

This is about transparency—making sure shareholders and the market can easily find the official data.

📇 Key Contacts & People

For follow-up questions, Pharming lists these specific contacts:

Investor Relations:

• Michael Levitan, VP Investor Relations & Corporate Communications
• Phone: +1 (908) 705 1696
• Email: [email protected]

Media Relations:

• Global: Saskia Mehring, Corporate Communications Manager
  • Phone: +31 6 28 32 60 41
  • Email: [email protected]
• U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
  • Phone: +1 (917) 882-9038
• Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
  • Phone: +31 6 53 81 64 27

Filing Signed By:

• Fabrice Chouraqui, Chief Executive Officer (CEO)

🧠 The Analogy

Filing this 6-K is like a student submitting the official notification that their year-long thesis is complete and ready for review. The 6-K is the notice, the Annual Report & 20-F are the actual thesis, and investors are the professors who now need to read it to grade the company's performance.

🧩 Final Takeaway

This is a routine but essential piece of corporate paperwork. Pharming has fulfilled its legal obligation to publish its 2025 annual financials. The real analysis begins when investors dig into the Annual Report and Form 20-F that this filing announces.